Why has the Cochlear (ASX:COH) share price been struggling lately?

Why is the medical device company underperforming the market?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Cochlear Limited (ASX: COH) share price has been underperforming in recent days.

Over the last month, shares in the hearing device company have fallen 2.6% and are currently trading for $235.28. Over the same period, the S&P/ASX 200 Index (ASX: XJO) is 1.53% lower.

So, why are Cochlear shares struggling at the moment?

Let's take a closer look.

laboratory workers looking disappointed

Image source: Getty Images

Could COVID be to blame?

The current COVID-19 outbreak in Australia's southeast could be one reason for the sluggish Cochlear share price of late.

New South Wales, Victoria, and the ACT are all under lockdown measures as the Delta variant runs rampant. This has put hospital capacity in those areas under increasing strain as coronavirus case numbers surge.

As a result, hospital elective surgery appointments are being cancelled — and this has even been mandated in Greater Sydney by the government.

Cochlear revealed in its full-year results that it generated more than 60% of its revenue from implant devices. So it's possible the struggling Cochlear share price may be a reflection of the fact surgeries have been delayed across Australia, especially in Sydney.

What else could be affecting Cochlear shares?

The company's shares have gone ex-dividend today.

This means investors who buy shares in a company on or after the day it goes ex-dividend are not entitled to receive the most recently announced dividend distribution.

The share price typically falls by the dividend amount on ex-dividend days as sellers who will keep the dividend seek to maximise returns.

Cochlear share price snapshot

While the Cochlear share price has been struggling over the last month, it's also had a pretty average year.

Over the past 12 months, Cochlear shares have appreciated 16%. The ASX 200, meanwhile, is up 24.5% over the same time.

It is slightly better reading since the beginning of 2021. Year-to-date, Cochlear shares have outpaced the ASX 200 by about 13 percentage points.

Cochlear has a market capitalisation of about $15.5 billion.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Scientists working in the laboratory and examining results.
Opinions

3 reasons to buy CSL shares today

The ASX biotech company has great growth potential this year.

Read more »

a man lies on his back on grass with his eyes shut and a contented look on his face as though he is dreaming
Broker Notes

With global populations ageing, are ResMed shares a good buy today?

A leading expert delivers his verdict on the outlook for ResMed shares.

Read more »

Wife and husband with a laptop on a sofa over the moon at good news.
Healthcare Shares

Why are Telix shares racing 8% higher today?

Telix shares are now 11% higher for the year-to-date.

Read more »

Health professional working on his laptop.
Healthcare Shares

Why Cochlear and ResMed shares could be strong buys

Wilsons has given its verdict on these big names and it's good.

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Healthcare Shares

Which exciting ASX All Ords stock is jumping on big news?

Let's see what is getting investors excited about this stock on Wednesday.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

Exciting clinical news for this ASX healthcare stock earns it a buy recommendation 

Is now the time to buy this exciting healthcare stock?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

How does Bell Potter rate these ASX healthcare stocks?

Let's see what the broker is saying about these shares.

Read more »

Ecstatic woman looking at her phone outside with her fist pumped.
Healthcare Shares

Why is this ASX 300 stock rocketing 17% today?

Let's see what is getting investors excited today.

Read more »